Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
group_6_ta_sansi_xing_diagnostics_of_sars-cov-2 [2021/02/02 01:34] nimojant [References] |
group_6_ta_sansi_xing_diagnostics_of_sars-cov-2 [2021/02/27 20:09] (current) dhalip1 [Diagnostics of SARS-Cov-2] |
||
|---|---|---|---|
| Line 206: | Line 206: | ||
| The current implementation of P-BEST is designed for a carrier rate of about 1% (Shental et al., 2020). When the carrier rate of a population is higher than this ideal value, the efficiency of the system changes and can lead to errors (Shental et al., 2020). At higher carrier rates too many pools would be PCR positive, and the number of samples identified by the method will be much larger than the number of expected carriers. This will prevent direct identification of the actual positive carriers in a single testing round and the user will have to retest the samples from the positive pools either individually or by using an alternate pooling design (Shental et al., 2020). | The current implementation of P-BEST is designed for a carrier rate of about 1% (Shental et al., 2020). When the carrier rate of a population is higher than this ideal value, the efficiency of the system changes and can lead to errors (Shental et al., 2020). At higher carrier rates too many pools would be PCR positive, and the number of samples identified by the method will be much larger than the number of expected carriers. This will prevent direct identification of the actual positive carriers in a single testing round and the user will have to retest the samples from the positive pools either individually or by using an alternate pooling design (Shental et al., 2020). | ||
| ===== Presentation Slides ===== | ===== Presentation Slides ===== | ||
| - | {{:coronavirus.pdf|}} | + | {{:diagnostics_of_sars-cov-2.pdf|}} |
| Line 222: | Line 222: | ||
| Chan, J. F.-W., Yip, C. C.-Y., To, K. K.-W., Tang, T. H.-C., Wong, S. C.-Y., Leung, K.-H., … Yuen, K.-Y. (2020). Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated <em>In Vitro</em> and with Clinical Specimens. Journal of Clinical Microbiology, 58(5), e00310-20. https://doi.org/10.1128/JCM.00310-20 | Chan, J. F.-W., Yip, C. C.-Y., To, K. K.-W., Tang, T. H.-C., Wong, S. C.-Y., Leung, K.-H., … Yuen, K.-Y. (2020). Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated <em>In Vitro</em> and with Clinical Specimens. Journal of Clinical Microbiology, 58(5), e00310-20. https://doi.org/10.1128/JCM.00310-20 | ||
| + | |||
| Chau, C. H., Strope, J. D., & Figg, W. D. (2020). COVID-19 Clinical Diagnostics and Testing Technology. The Journal of Human Pharmacology and Drug Therapy, 40(8), 857-868. | Chau, C. H., Strope, J. D., & Figg, W. D. (2020). COVID-19 Clinical Diagnostics and Testing Technology. The Journal of Human Pharmacology and Drug Therapy, 40(8), 857-868. | ||
